Department of Cardiology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium.
Department of Cardiology, AZ Sint-Jan Brugge-Oostende, Brugge, Belgium.
JACC Clin Electrophysiol. 2022 Mar;8(3):367-376. doi: 10.1016/j.jacep.2021.11.019. Epub 2022 Feb 23.
In this study, the authors sought to investigate the added value of vein of Marshall ethanol infusion (VOMEt) as first step in facilitating radiofrequency (RF)-guided mitral isthmus (MI) block.
Achieving MI block with the use of RF ablation is challenging.
Seventy patients planned for MI ablation were randomized 1:1 to VOMEt as a first step preceding RF (endocardial and epicardial, VOM group) vs RF ablation as a first step preceding VOMEt (RF group). The study end point was incidence of MI block after RF ablation and after the 2 steps.
In VOM, VOMEt was successful in 30/35 patients (86%) resulting in a low-voltage area of 12 ± 7.4 cm and MI block in 2/35 patients (6%). VOM, compared with RF, was associated with higher incidence of MI block after endocardial (46% vs 11%; P < 0.001) and epicardial ablation (94% vs 43%; P < 0.001), with fewer endocardial applications (4 vs 11 vs 4; P < 0.001) and similar epicardial applications (7 vs 8; P = 0.68). Incidence of MI block after the 2 steps was 94% vs 63% (P = 0.001) in VOM vs RF, respectively. Additional touch-up RF ablation in both groups resulted in final MI block in all but 1 patient (99%).
VOMEt as a first step in RF-guided MI line ablation significantly reduced the number of RF applications needed to achieve MI block, even if the sequence of the ablation steps did not affect the final incidence of block. (Evaluation of Vein of Marshall Ethanol Infusion During Left Atrial Linear Ablation in Patients With Persistent Atrial Fibrillation [MARSHALINE]; NCT04124328).
本研究旨在探讨Marshall 静脉乙醇灌注(VOMEt)作为辅助射频(RF)引导二尖瓣峡部(MI)阻滞的第一步的附加价值。
使用 RF 消融实现 MI 阻滞具有挑战性。
70 例计划行 MI 消融的患者被随机分为 1:1 接受 VOMEt 作为 RF 消融前的第一步(心内膜和心外膜,VOM 组)或 RF 消融作为 VOMEt 前的第一步(RF 组)。研究终点是 RF 消融后和两步后 MI 阻滞的发生率。
在 VOMEt 中,35 例患者中的 30 例(86%)成功,产生 12 ± 7.4cm 的低电压区,2 例(6%)出现 MI 阻滞。与 RF 相比,VOMEt 在心内膜消融后(46%比 11%;P<0.001)和心外膜消融后(94%比 43%;P<0.001)更易导致 MI 阻滞,心内膜消融应用次数更少(4 次比 11 次比 4 次;P<0.001),心外膜消融应用次数相似(7 次比 8 次;P=0.68)。两步后 MI 阻滞的发生率分别为 VOMEt 组 94%和 RF 组 63%(P=0.001)。在两组中,追加的触发性 RF 消融最终使除 1 例患者(99%)外的所有患者均实现 MI 阻滞。
VOMEt 作为 RF 引导 MI 线消融的第一步,即使消融步骤的顺序不影响阻滞的最终发生率,也显著减少了实现 MI 阻滞所需的 RF 应用次数。(MARSHALINE 研究:Marshall 静脉乙醇灌注在持续性心房颤动患者左心房线性消融中的评估;NCT04124328)。